Searchable abstracts of presentations at key conferences in endocrinology

ea0090oc8.2 | Oral Communications 8: Calcium and Bone | ECE2023

Eneboparatide, a Novel PTH-1 Receptor Agonist, Has No Impact on Bone Parameters Following Chronic Treatment of Non-Human Primates

Ravel Guillaume , Delale Thomas , Milano Stephane , Chirat Sophie , Verset Michael , Latronico Emilie , Allas Soraya , Culler Michael D.

Eneboparatide (AZP-3601) is a novel, synthetic, 36-amino-acid peptide agonist of the parathyroid hormone type 1 receptor (PTHR1), with potent selectivity for the R0 conformation. This results in prolonged calcemic responses, while having a short circulating half-life. Eneboparatide is being developed for the treatment of chronic hypoparathyroidism (cHP). Studies in hypoparathyroid animal models and, most recently, in hypoparathyroid patients, have demonstrated that eneboparati...

ea0090rc7.3 | Rapid Communications 7: Pituitary and Neuroendocrinology 2 | ECE2023

AZP-3813, a bicyclic, 16-amino acid peptide antagonist of the human growth hormone receptor, effectively suppresses IGF1 in beagle dogs

Ravel Guillaume , Chalmey Clementine , Berardet Corentin , Duracher David , Kurasaki Haruaki , Tomiyama Tatsuya , Reid Patrick , Culler Michael D.

Medical treatment of acromegaly is based on either suppressing pituitary growth hormone (GH) secretion or by inhibiting GH action by preventing interaction with its receptor in order to suppress the elevated levels of insulin-like growth factor 1 (IGF1). AZP-3813 is a 16-amino acid, bicyclic peptide antagonist of the GH receptor (GHR) with KD of 1.9 nM for the human GHR. Previously, AZP-3813 was demonstrated to suppress IGF1 secretion in juvenile rats in a dose-rela...